Actively Recruiting
Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Led by Jemincare · Updated on 2025-07-03
135
Participants Needed
1
Research Sites
115 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003142 in Participants with Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
CONDITIONS
Official Title
Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to understand the trial procedures and provide written informed consent
- Age between 18 to 55 years, male or female
- Diagnosed with autosomal dominant polycystic kidney disease (ADPKD) before randomization
- Meet criteria for rapidly progressive ADPKD
You will not qualify if you...
- Taken tolvaptan or other ADPKD treatments within 12 weeks before screening
- Assessed likely to need diuretics during the trial
- Unable to feel thirst or have difficulty with fluid or food intake
- Previously had decompression surgery for renal cysts
- Had major surgery within 12 weeks before signing consent
- Unable to comply with trial requirements or be evaluated by the trial investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
Research Team
X
xiaojun zhou
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here